Ribosome Biogenesis: A Central Player in Cancer Metastasis and Therapeutic Resistance

Abstract Ribosomes are a complex ensemble of rRNA and ribosomal proteins that function as mRNA translation machines. Ribosome biogenesis is a multistep process that begins in the nucleolus and concludes in the cytoplasm. The process is tightly controlled by multiple checkpoint and surveillance pathways. Perturbations in these checkpoints and pathways can lead to hyperactivation of ribosome biogenesis. Emerging evidence suggests that cancer cells harbor a specialized class of ribosomes (onco-ribosomes) that facilitates the oncogenic translation program, modulates cellular functions, and promotes metabolic rewiring. Mutations in ribosomal proteins, rRNA processing, and ribosome assembly factors result in ribosomopathies that are associated with an increased risk of developing malignancies. Recent studies have linked mutations in ribosomal proteins and aberrant ribosomes with poor prognosis, highlighting ribosome-targeted therapy as a promising approach for treating patients with cancer. Here, we summarize various aspects of dysregulation of ribosome biogenesis and the impact of resultant onco-ribosomes on malignant tumor behavior, therapeutic resistance, and clinical outcome. Ribosome biogenesis is a promising therapeutic target, and understanding the important determinants of this process will allow for improved and perhaps selective therapeutic strategies to target ribosome biosynthesis.

[1]  R. Pearson,et al.  Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy , 2021, Signal Transduction and Targeted Therapy.

[2]  K. Prasanth,et al.  Regulatory roles of nucleolus organizer region-derived long non-coding RNAs , 2021, Mammalian Genome.

[3]  Lin-lin Sun,et al.  Ribosome Proteins Represented by RPL27A Mark the Development and Metastasis of Triple-Negative Breast Cancer in Mouse and Human , 2021, Frontiers in Cell and Developmental Biology.

[4]  R. Pearson,et al.  CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition , 2021, Molecular Cancer Therapeutics.

[5]  A. Lund,et al.  Translational control through ribosome heterogeneity and functional specialization. , 2021, Trends in biochemical sciences.

[6]  Z. Ren,et al.  RPL19 Is a Prognostic Biomarker and Promotes Tumor Progression in Hepatocellular Carcinoma , 2021, Frontiers in Cell and Developmental Biology.

[7]  Alexa L. Mattheyses,et al.  Novel role of the dietary flavonoid fisetin in suppressing rRNA biogenesis , 2021, Laboratory Investigation.

[8]  K. Stamatopoulos,et al.  RPS15 mutations rewire RNA translation in chronic lymphocytic leukemia. , 2021, Blood advances.

[9]  Shah Adil Ishtiyaq Ahmad,et al.  Ribosome Incorporation Induces EMT-like Phenomenon with Cell Cycle Arrest in Human Breast Cancer Cell , 2021, Cells Tissues Organs.

[10]  F. André,et al.  Ribosomal RNA 2′ O-methylation as a novel layer of inter-tumour heterogeneity in breast cancer , 2021, NAR cancer.

[11]  D. Haber,et al.  Translational Regulation of Cancer Metastasis , 2021, Cancer Research.

[12]  K. Grønbæk,et al.  Profiling of ribose methylations in ribosomal RNA from diffuse large B-cell lymphoma patients for evaluation of ribosomes as drug targets , 2020, NAR cancer.

[13]  M. Alsabbagh.  Dyskeratosis congenita: a literature review , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[14]  A. Rustgi,et al.  EMT, MET, Plasticity, and Tumor Metastasis. , 2020, Trends in cell biology.

[15]  S. Xiao,et al.  RPL41 sensitizes retinoblastoma cells to chemotherapeutic drugs via ATF4 degradation , 2020, Journal of cellular physiology.

[16]  Atique U. Ahmed,et al.  Ribosomal protein S11 influences glioma response to TOP2 poisons , 2020, Oncogene.

[17]  E. Berns,et al.  CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer , 2020, Nature Communications.

[18]  J. Greenblatt,et al.  Nucleolar RNA polymerase II drives ribosome biogenesis , 2020, Nature.

[19]  Jianlong Wang,et al.  Ribosome heterogeneity in stem cells and development , 2020, The Journal of cell biology.

[20]  S. Baserga,et al.  MicroRNAs and long non-coding RNAs as novel regulators of ribosome biogenesis , 2020, Biochemical Society transactions.

[21]  I. Mihalek,et al.  Cancer-associated mutations in the ribosomal protein L5 gene dysregulate the HDM2/p53-mediated ribosome biogenesis checkpoint , 2020, Oncogene.

[22]  J. Krijgsveld,et al.  Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for Acute Myeloid Leukemia cell proliferation. , 2020, Blood.

[23]  Ben S. Wittner,et al.  Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis , 2020, Science.

[24]  R. Hannan,et al.  Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age , 2020, Cells.

[25]  J. Ule,et al.  Subcellular mRNA Localization Regulates Ribosome Biogenesis in Migrating Cells , 2019, bioRxiv.

[26]  C. Bieberich,et al.  Effective targeting of RNA polymerase I in treatment‐resistant prostate cancer , 2019, The Prostate.

[27]  A. Mele,et al.  Germline NPM1 mutations lead to altered rRNA 2’-O-methylation and cause dyskeratosis congenita , 2019, Nature Genetics.

[28]  P. Pandolfi,et al.  Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program , 2019, Acta Neuropathologica.

[29]  Wei Jiang,et al.  Ribosomal Protein L15 is involved in Colon Carcinogenesis , 2019, International journal of medical sciences.

[30]  Sergey O. Sulima,et al.  Hallmarks of ribosomopathies , 2019, Nucleic acids research.

[31]  O. Gadal,et al.  Meeting report from the first European OddPols meeting: Toulouse 2018. , 2019, Gene.

[32]  J. Bergh,et al.  Ribosome biogenesis during cell cycle arrest fuels EMT in development and disease , 2019, Nature Communications.

[33]  Yibin Kang,et al.  Context-dependent EMT programs in cancer metastasis , 2019, The Journal of experimental medicine.

[34]  Xuezhu Feng,et al.  The Functions of Non-coding RNAs in rRNA Regulation , 2019, Front. Genet..

[35]  Jung-Hoon Lee,et al.  Molecular pathogenesis of myelodysplastic syndromes with deletion 5q , 2019, European journal of haematology.

[36]  A. Aspesi,et al.  Rare ribosomopathies: insights into mechanisms of cancer , 2019, Nature Reviews Cancer.

[37]  Rui-chun Li,et al.  Knockdown of RPL34 inhibits the proliferation and migration of glioma cells through the inactivation of JAK/STAT3 signaling pathway , 2018, Journal of cellular biochemistry.

[38]  A. Cervantes,et al.  NRF2 through RPS6 Activation Is Related to Anti-HER2 Drug Resistance in HER2-Amplified Gastric Cancer , 2018, Clinical Cancer Research.

[39]  S. Gygi,et al.  Altered patterns of global protein synthesis and translational fidelity in RPS15-mutated chronic lymphocytic leukemia. , 2018, Blood.

[40]  A. Brenner,et al.  MiR-584-5p potentiates vincristine and radiation response by inducing spindle defects and DNA damage in medulloblastoma , 2018, Nature Communications.

[41]  M. Barna,et al.  The Discovery of Ribosome Heterogeneity and Its Implications for Gene Regulation and Organismal Life. , 2018, Molecular cell.

[42]  J. Meijerink,et al.  The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL , 2018, Leukemia.

[43]  K. Nagashima,et al.  Metarrestin, a perinucleolar compartment inhibitor, effectively suppresses metastasis , 2018, Science Translational Medicine.

[44]  Alexandre David,et al.  The ribosome, (slow) beating heart of cancer (stem) cell , 2018, Oncogenesis.

[45]  M. Tan,et al.  Inactivation of ribosomal protein S27-like confers radiosensitivity via the Mdm2-p53 and Mdm2–MRN–ATM axes , 2018, Cell Death & Disease.

[46]  D. Lyden,et al.  Variant ribosomal RNA alleles are conserved and exhibit tissue-specific expression , 2018, Science Advances.

[47]  Wanyeon Kim,et al.  RNF138-mediated ubiquitination of rpS3 is required for resistance of glioblastoma cells to radiation-induced apoptosis , 2018, Experimental & Molecular Medicine.

[48]  George Thomas,et al.  Ribosome biogenesis in cancer: new players and therapeutic avenues , 2017, Nature Reviews Cancer.

[49]  J. Meijerink,et al.  The T-cell leukemia associated ribosomal RPL10 R98S mutation enhances JAK-STAT signaling , 2017, Leukemia.

[50]  Wen-Chang Chang,et al.  MDM2 Degrades Deacetylated Nucleolin Through Ubiquitination to Promote Glioma Stem-Like Cell Enrichment for Chemotherapeutic Resistance , 2017, Molecular Neurobiology.

[51]  Wei Wei,et al.  Influence of the RPL34 gene on the growth and metastasis of oral squamous cell carcinoma cells. , 2017, Archives of oral biology.

[52]  J. Dinman,et al.  How Ribosomes Translate Cancer. , 2017, Cancer discovery.

[53]  B. Lemos,et al.  Ribosomal DNA copy number amplification and loss in human cancers is linked to tumor genetic context, nucleolus activity, and proliferation , 2017, PLoS genetics.

[54]  Zachary C. Dobbin,et al.  Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer , 2017, Clinical Cancer Research.

[55]  Song-yan Li,et al.  BMH-21 inhibits viability and induces apoptosis by p53-dependent nucleolar stress responses in SKOV3 ovarian cancer cells , 2017, Oncology reports.

[56]  J. Zuber,et al.  Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. , 2017, Blood.

[57]  Xiao Li,et al.  Ribosomal protein L23 negatively regulates cellular apoptosis via the RPL23/Miz-1/c-Myc circuit in higher-risk myelodysplastic syndrome , 2017, Scientific Reports.

[58]  J. Keats,et al.  RNA Polymerase I Inhibition with CX‐5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma , 2017, British journal of haematology.

[59]  Yves Pommier,et al.  A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress , 2017, Nature Medicine.

[60]  Baoyan Bai,et al.  Novel Assay to Detect RNA Polymerase I Activity In Vivo , 2017, Molecular Cancer Research.

[61]  K. Entian,et al.  Tuning the ribosome: The influence of rRNA modification on eukaryotic ribosome biogenesis and function , 2016, RNA biology.

[62]  P. Broderick,et al.  Validation of Recently Proposed Colorectal Cancer Susceptibility Gene Variants in an Analysis of Families and Patients-a Systematic Review. , 2017, Gastroenterology.

[63]  G. Botti,et al.  rpL3 promotes the apoptosis of p53 mutated lung cancer cells by down-regulating CBS and NFκB upon 5-FU treatment , 2016, Scientific Reports.

[64]  Jinmin Zhao,et al.  Highly expressed ribosomal protein L34 indicates poor prognosis in osteosarcoma and its knockdown suppresses osteosarcoma proliferation probably through translational control , 2016, Scientific Reports.

[65]  Mihaela Zavolan,et al.  Patterns of ribosomal protein expression specify normal and malignant human cells , 2016, Genome Biology.

[66]  Fenggui Wei,et al.  Ribosomal protein L34 promotes the proliferation, invasion and metastasis of pancreatic cancer cells , 2016, Oncotarget.

[67]  S. Baserga,et al.  Probing the mechanisms underlying human diseases in making ribosomes. , 2016, Biochemical Society transactions.

[68]  Anthony M. C. Brown,et al.  Wnt5a Signals through DVL1 to Repress Ribosomal DNA Transcription by RNA Polymerase I , 2016, PLoS genetics.

[69]  K. Khanna,et al.  Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling , 2016, Oncotarget.

[70]  Jianming Xu,et al.  Ribosomal protein S15A promotes malignant transformation and predicts poor outcome in colorectal cancer through misregulation of p53 signaling pathway. , 2016, International journal of oncology.

[71]  F. Zhan,et al.  Overexpression of RPS27a contributes to enhanced chemoresistance of CML cells to imatinib by the transactivated STAT3 , 2016, Oncotarget.

[72]  K. Stamatopoulos,et al.  Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. , 2016, Blood.

[73]  K. Rippe,et al.  Alu element‐containing RNAs maintain nucleolar structure and function , 2015, The EMBO journal.

[74]  R. Weinberg,et al.  Epithelial-Mesenchymal Plasticity: A Central Regulator of Cancer Progression. , 2015, Trends in cell biology.

[75]  S. Nelson,et al.  Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients , 2015, PloS one.

[76]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[77]  O. Mäkitie,et al.  Cartilage-Hair Hypoplasia – Anauxetic Dysplasia Spectrum Disorders , 2015 .

[78]  P. Brown,et al.  rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis , 2015, Oncotarget.

[79]  D. Lafontaine,et al.  Noncoding RNAs in eukaryotic ribosome biogenesis and function , 2015, Nature Structural &Molecular Biology.

[80]  S. Scherer,et al.  Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency , 2014, Gastroenterology.

[81]  Camille B Francisco,et al.  Microenvironment and Immunology Cancer Cells Exploit eIF 4 E 2-Directed Synthesis of Hypoxia Response Proteins to Drive Tumor Progression , 2014 .

[82]  C. Bieberich,et al.  A targeting modality for destruction of RNA polymerase I that possesses anticancer activity. , 2014, Cancer cell.

[83]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[84]  J. Saurin,et al.  p53 Acts as a Safeguard of Translational Control by Regulating Fibrillarin and rRNA Methylation in Cancer , 2013, Cancer Cell.

[85]  Yu-Che Cheng,et al.  Ribosomal Protein S27-Like in Colorectal Cancer: A Candidate for Predicting Prognoses , 2013, PloS one.

[86]  Stein Aerts,et al.  Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia , 2012, Nature Genetics.

[87]  Joonhee Kim,et al.  Phosphorylation of Ribosomal Protein S3 and Antiapoptotic TRAF2 Protein Mediates Radioresistance in Non-small Cell Lung Cancer Cells* , 2012, The Journal of Biological Chemistry.

[88]  A. Look,et al.  Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. , 2012, Blood.

[89]  B. Hemmings,et al.  Translation regulation as a therapeutic target in cancer. , 2012, Cancer research.

[90]  M. Ge,et al.  Silencing expression of ribosomal protein L26 and L29 by RNA interfering inhibits proliferation of human pancreatic cancer PANC-1 cells , 2012, Molecular and Cellular Biochemistry.

[91]  Carleen Cullinane,et al.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.

[92]  Adam Siddiqui-Jain,et al.  Discovery of CX-5461, the First Direct and Selective Inhibitor of RNA Polymerase I, for Cancer Therapeutics. , 2012, ACS medicinal chemistry letters.

[93]  L. Montanaro,et al.  Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. , 2012, Cancer research.

[94]  D. Schneider.  RNA polymerase I activity is regulated at multiple steps in the transcription cycle: recent insights into factors that influence transcription elongation. , 2012, Gene.

[95]  R. Horos,et al.  Ribosomal deficiencies in Diamond-Blackfan anemia impair translation of transcripts essential for differentiation of murine and human erythroblasts. , 2012, Blood.

[96]  Jae K. Lee,et al.  Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy. , 2011, Neoplasia.

[97]  Haifeng Jin,et al.  Downregulation of RPL6 by siRNA Inhibits Proliferation and Cell Cycle Progression of Human Gastric Cancer Cell Lines , 2011, PloS one.

[98]  C. Cooper,et al.  siRNA Knockdown of Ribosomal Protein Gene RPL19 Abrogates the Aggressive Phenotype of Human Prostate Cancer , 2011, PloS one.

[99]  P. M. Do,et al.  Coilin participates in the suppression of RNA polymerase I in response to cisplatin-induced DNA damage , 2011, Molecular biology of the cell.

[100]  R. Hannan,et al.  Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. , 2011, Cancer research.

[101]  Shuang-yin Han,et al.  Human ribosomal protein S13 promotes gastric cancer growth through down-regulating p27Kip1 , 2009, Journal of cellular and molecular medicine.

[102]  Karita Peltonen,et al.  Identification of Novel p53 Pathway Activating Small-Molecule Compounds Reveals Unexpected Similarities with Known Therapeutic Agents , 2010, PloS one.

[103]  C. Deisenroth,et al.  Ribosome biogenesis surveillance: probing the ribosomal protein-Mdm2-p53 pathway , 2010, Oncogene.

[104]  S. Formenti,et al.  Translational control in cancer , 2010, Nature Reviews Cancer.

[105]  D. Felsher,et al.  MYC as a regulator of ribosome biogenesis and protein synthesis , 2010, Nature Reviews Cancer.

[106]  Shan Wang,et al.  RPL41, a small ribosomal peptide deregulated in tumors, is essential for mitosis and centrosome integrity. , 2010, Neoplasia.

[107]  E. Kremmer,et al.  Chemotherapeutic Drugs Inhibit Ribosome Biogenesis at Various Levels* , 2010, The Journal of Biological Chemistry.

[108]  I. Grummt,et al.  The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer. , 2010, Annual review of pharmacology and toxicology.

[109]  D. Bazett-Jones,et al.  Structure and function of the perinucleolar compartment in cancer cells. , 2010, Cold Spring Harbor symposia on quantitative biology.

[110]  Octavio A. Quiñones,et al.  An Intergenic Non-Coding rRNA Correlated with Expression of the rRNA and Frequency of an rRNA Single Nucleotide Polymorphism in Lung Cancer Cells , 2009, PloS one.

[111]  Christopher P Austin,et al.  Automated High-Content Screening for Compounds That Disassemble the Perinucleolar Compartment , 2009, Journal of biomolecular screening.

[112]  M. Stearns,et al.  RPS2: a novel therapeutic target in prostate cancer , 2009, Journal of experimental & clinical cancer research : CR.

[113]  K. Aldape,et al.  Elevated Phospho-S6 Expression Is Associated with Metastasis in Adenocarcinoma of the Lung , 2008, Clinical Cancer Research.

[114]  Sui Huang,et al.  Perinucleolar compartment prevalence is a phenotypic pancancer marker of malignancy , 2008, Cancer.

[115]  Yong-jie Lu,et al.  Nascent pre‐rRNA overexpression correlates with an adverse prognosis in alveolar rhabdomyosarcoma , 2006, Genes, chromosomes & cancer.

[116]  M. Toyota,et al.  Activation of the ribosomal protein L13 gene in human gastrointestinal cancer. , 2006, International journal of molecular medicine.

[117]  Xiao-Jun Li,et al.  Overexpression of ribosomal protein L15 is associated with cell proliferation in gastric cancer , 2006, BMC Cancer.

[118]  C. Foster,et al.  Ribosomal Protein L19 Is a Prognostic Marker for Human Prostate Cancer , 2006, Clinical Cancer Research.

[119]  D. Fan,et al.  Regulation of multidrug resistance by ribosomal protein L6 in gastric cancer cells , 2005, Cancer biology & therapy.

[120]  Sui Huang,et al.  Perinucleolar compartment prevalence has an independent prognostic value for breast cancer. , 2005, Cancer research.

[121]  D. Treré,et al.  Relationship between interphase AgNOR distribution and nucleolar size in cancer cells , 1992, The Histochemical Journal.

[122]  Yumei Zhang,et al.  Ribosomal proteins S13 and L23 promote multidrug resistance in gastric cancer cells by suppressing drug-induced apoptosis. , 2004, Experimental cell research.

[123]  G. Edelman,et al.  The ribosome filter hypothesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[124]  L. Comai,et al.  Repression of RNA Polymerase I Transcription by the Tumor Suppressor p53 , 2000, Molecular and Cellular Biology.

[125]  L. Terracciano,et al.  Proliferation, but not growth, blocked by conditional deletion of 40S ribosomal protein S6. , 2000, Science.

[126]  L. Montanaro,et al.  Nucleolar function and size in cancer cells. , 1998, The American journal of pathology.

[127]  R. Peterkova,et al.  Drug-induced changes of rRNA biosynthesis--a marker of toxic damage to embryonal cell population. , 1993, Functional and developmental morphology.

[128]  K. Smetana,et al.  Nucleolar silver stained granules in rat Yoshida sarcoma cells after RNA synthesis inhibition. , 1981, Neoplasma.